ICP-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Brenner has been funded by agencies including the March of Dimes, the Burroughs Wellcome Fund, the Beckman Foundation, the Lung Cancer Research Foundation, the Bill & Melinda Gates Foundation, the Leukemia & Lymphoma Society, the National Science Foundation the National Institutes of Health and the Sigrid Juselius Foundation.
Chuck steak is a cut of beef and is part of the sub-prime cut known as the chuck. The typical chuck steak is a rectangular cut, about 2.5 cm (1 inch) thick and containing parts of the shoulder bones of cattle, and is often known as a "7-bone steak," as the shape of the shoulder bone in cross-section resembles the numeral '7'. This cut is usually grilled or broiled; a thicker version is sold as a "7-bone roast" or "chuck roast" and is usually cooked with liquid as a pot roast. The bone-in chuck steak or roast is one of the more economical cuts of beef. In the United Kingdom, this part is commonly referred to as "braising steak". It is particularly popular for use as ground beef for its richness of flavor and balance of meat and fat.
=== Descriptions of deficiency effects === Between 1849 and 1887, Thomas Addison described a case of pernicious anemia, William Osler and William Gardner first described a case of neuropathy, Hayem described large red cells in the peripheral blood in this condition, which he called "giant blood corpuscles" (now called macrocytes), Paul Ehrlich identified megaloblasts in the bone marrow, and Ludwig Lichtheim described a case of myelopathy.
Sources: en.wikipedia.org
2026 United States federal budget – $6.8 trillion (submitted 2025 by President Trump) 2025 United States federal budget – $7 trillion (submitted 2024 by President Biden) 2024 United States federal budget – $6.8 trillion (submitted 2023 by President Biden) 2023 United States federal budget – $6.1 trillion (submitted 2022 by President Biden) 2022 United States federal budget – $6.3 trillion (submitted 2021 by President Biden) 2021 United States federal budget – $6.8 trillion (submitted 2020 by President Trump) 2020 United States federal budget – $6.5 trillion (submitted 2019 by President Trump) 2019 United States federal budget – $4.4 trillion (submitted 2018 by President Trump) 2018 United States federal budget – $4.1 trillion (submitted 2017 by President Trump) 2017 United States federal budget – $4.2 trillion (submitted 2016 by President Obama) 2016 United States federal budget – $4 trillion (submitted 2015 by President Obama) 2015 United States federal budget – $3.9 trillion (submitted 2014 by President Obama) 2014 United States federal budget – $3.5 trillion (submitted 2013 by President Obama) 2013 United States federal budget – $3.8 trillion (submitted 2012 by President Obama) 2012 United States federal budget – $3.7 trillion (submitted 2011 by President Obama) 2011 United States federal budget – $3.8 trillion (submitted 2010 by President Obama) 2010 United States federal budget – $3.6 trillion (submitted 2009 by President Obama) 2009 United States federal budget – $3.5 trillion (submitted 2008 by President Bush) 2008 United States federal budget – $2.9 trillion (submitted 2007 by President Bush) 2007 United States federal budget – $2.8 trillion (submitted 2006 by President Bush) 2006 United States federal budget – $2.7 trillion (submitted 2005 by President Bush) 2005 United States federal budget – $2.4 trillion (submitted 2004 by President Bush) 2004 United States federal budget – $2.3 trillion (submitted 2003 by President Bush) 2003 United States federal budget – $2.2 trillion (submitted 2002 by President Bush) 2002 United States federal budget – $2 trillion (submitted 2001 by President Bush) 2001 United States federal budget – $1.9 trillion (submitted 2000 by President Clinton) 2000 United States federal budget – $1.8 trillion (submitted 1999 by President Clinton) 1999 United States federal budget – $1.7 trillion (submitted 1998 by President Clinton) 1998 United States federal budget – $1.7 trillion (submitted 1997 by President Clinton) 1997 United States federal budget – $1.6 trillion (submitted 1996 by President Clinton) 1996 United States federal budget – $1.6 trillion (submitted 1995 by President Clinton) The budget year runs from October 1 to September 30 the following year and is submitted by the President to Congress prior to October for the following year. In this way the budget of 2013 is submitted before the end of September 2012. This means that the budget of 2001 was submitted by Bill Clinton and was in force during most of George W. Bush's first year in office. The budget submitted by George W. Bush in his last year in office was the budget of 2009, which was in force through most of Barack Obama's first year in office. The President's budget also contains revenue and spending projections for the current fiscal year, the coming fiscal years, as well as several future fiscal years. In recent years, the President's budget contained projections five years into the future. The Congressional Budget Office (CBO) issues a "Budget and Economic Outlook" each January and an analysis of the President's budget each March. CBO also issues an updated budget and economic outlook in August. Actual budget data for prior years is available from the Congressional Budget Office; see the "Historical Budget Data" links on the main page of "The Budget and Economic Outlook". and from the Office of Management and Budget (OMB).
The quantitative "reading" is usually based on detection of intensity of transmitted light by spectrophotometry, which involves quantitation of transmission of some specific wavelength of light through the liquid (as well as the transparent bottom of the well in the multiple-well plate format). The sensitivity of detection depends on amplification of the signal during the analytic reactions. Since enzyme reactions are very well known amplification processes, the signal is generated by enzymes which are linked to the detection reagents in fixed proportions to allow accurate quantification, and thus the name "enzyme-linked". The analyte is also called the ligand because it will specifically bind or ligate to a detection reagent, thus ELISA falls under the bigger category of ligand binding assays. The ligand-specific binding reagent is "immobilized", i.e., usually coated and dried onto the transparent bottom and sometimes also side wall of a well (the stationary "solid phase"/"solid substrate" here as opposed to solid microparticle/beads that can be washed away), which is usually constructed as a multiple-well plate known as the "ELISA plate". Conventionally, like other forms of immunoassays, the specificity of antigen-antibody type reaction is used because it is easy to raise an antibody specifically against an antigen in bulk as a reagent. Alternatively, if the analyte itself is an antibody, its target antigen can be used as the binding reagent.
Further, they found that the hormone was produced from pancreatic islets by cells differing from the insulin-producing beta cells; presumably these were alpha cells. It was de Duve who realised that Sutherland's HG factor was in fact the same as glucagon; this rediscovery led to its permanent name, which de Duve reintroduced it in 1951. The pair's work showed that glucagon was the major hormone influencing the breakdown of glycogen in the liver—the process known as glycogenolysis—by which more sugars are produced and released into the blood. De Duve's original hypothesis that glucagon was produced by pancreatic alpha cells was proven correct when he demonstrated that selectively cobalt-damaged alpha cells stopped producing glucagon in guinea pigs; he finally isolated the purified hormone in 1953, including those from birds. De Duve was first to hypothesise that the production of insulin (which decreased blood sugar levels), stimulated the uptake of glucose in the liver; he also proposed that a mechanism was in-place to balance the productions of insulin and glucagon in order to maintain normal blood sugar level, (see homeostasis). This idea was much disputed at the time, but his rediscovery of glucagon confirmed his theses. In 1953 he experimentally demonstrated that glucagon did influence the production (and thus the uptake) of glucose.
=== Non-fraternization === Fraternization between senior cadres and PLA officers is prohibited without authorization. Politburo members must apply to the Politburo Standing Committee before visiting PLA units and once approved, visits must be arranged by the CMC. CMC approval is required before a PLA general can be involved in national or regional civil affairs.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.